0001437749-16-028681.txt : 20160330 0001437749-16-028681.hdr.sgml : 20160330 20160330163013 ACCESSION NUMBER: 0001437749-16-028681 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160325 ITEM INFORMATION: Other Events FILED AS OF DATE: 20160330 DATE AS OF CHANGE: 20160330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI VACCINES INC. CENTRAL INDEX KEY: 0000704159 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930589534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18188 FILM NUMBER: 161540067 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6178303031 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: PAULSON CAPITAL (DELAWARE) CORP. DATE OF NAME CHANGE: 20140326 FORMER COMPANY: FORMER CONFORMED NAME: PAULSON CAPITAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 vbiv20160330_8k.htm FORM 8-K vbiv20160330_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT 

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report: March 25, 2016

(Date of earliest event reported)

 

 

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction

of incorporation)

0-18188

(Commission File

Number)

93-0589534

(IRS Employer

Identification Number)

 

 

222 3rd Street, Suite 2241

Cambridge, Massachusetts

(Address of principal executive offices)

  

02142

(Zip Code)

 

(617) 830-3031

(Registrant’s telephone number, including area code)

  

 

(Former Name or Former Address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

ITEM 8.01            OTHER EVENTS

 

As previously disclosed, a class action complaint captioned Furlong et al. v. VBI Vaccines, Inc. et al. (as amended, the “Complaint”) was filed in the United States District Court, Southern District of New York (the “Court”) against VBI Vaccines Inc. (the “Company” or “VBI”) and certain individuals who were directors of the Company as of the date of the Company’s 2013 annual meeting of stockholders, making claims arising under Section 20(a) and Section 14(a) of the Securities Exchange Act of 1934, as amended, and Rule 14a-9 promulgated thereunder by the Securities and Exchange Commission (the “SEC”). On March 25, 2016, the Company’s motion to dismiss the Complaint was granted with prejudice, pursuant to an Opinion & Order of the Court entered on that date, on the grounds that the Complaint fails to adequately plead any actionable misleading statement or omission.

 

 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 30, 2016

 

 

VBI VACCINES INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Jeff Baxter

 

 

 

Jeff Baxter

 

 

 

Chief Executive Officer